Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Remimazolam plus remifentanil sedation and analgesia in ECMO patients
ChiCTR2100053180Phase 4Recruiting
- Sponsor
- Sichuan Provincial People's Hospital
- Start
- Jan 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of remimazolam in acute respiratory distress syndrome (ARDS) and cardiogenic shock, sponsored by Sichuan Provincial People's Hospital. Primary endpoints: Hemodynamic status and Bispectral index (BIS). Started Jan 2022; status: recruiting.
02
Drugs
remimazolam
03
Conditions
acute respiratory distress syndrome (ARDS)cardiogenic shock
Beyond the preview
Go deeper on ChiCTR2100053180.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100053180.